NDAQ

Over the past six months (April - October 2026), Nasdaq's stock price increased by 9.14% in the past three months and 4.56% over the last 12 months, though it decreased by 4.84% in the past month. Key events included stronger-than-expected Q2 2026 earnings, with $1.07 per share versus an estimated $0.98 and revenue rising 14.9% year-over-year to $2.53 billion. Analyst ratings varied, with Morgan Stanley and Barclays lowering price targets but maintaining 'overweight' ratings, Piper Sandler and TD Cowen raising targets with 'overweight'/'buy' ratings, and Zacks Research downgrading to 'hold'. The launch of the Texas Stock Exchange and competition from Intercontinental Exchange and crypto platforms like Coinbase were noted as competitive pressures. Nasdaq announced a strategic initiative to introduce a new 9 p.m.-to-4 a.m. ET night session starting December 6, 2026, extending trading to 23 hours a day. Moderna, Inc. is scheduled to join the Nasdaq-100 Index, replacing Warner Bros. Discovery, effective October 9, 2026. The company also demonstrated strong shareholder returns, repurchasing $903 million of stock in the first half of 2026 and raising its quarterly dividend for the 14th consecutive year.